Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X. Zhu, Yvonne H. Sada, Richard S. Finn et al.|The Lancet Oncology|2018Cited by 2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Sérgio de Azevedo et al.|The Lancet|2023Cited by 514
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenibManabu Morimoto, Katsuaki Tanaka, Kazushi Numata et al.|Hepatology Research|2011Cited by 77
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Katsuaki Tanaka, Manabu Morimoto et al.|BMC Cancer|2019Cited by 77
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trialMasatoshi Kudo, Takuji Okusaka, Michihisa Moriguchi et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 60